GSK bolsters oncology portfolio with $10.6bn Nuvalent
GSK is to acquire Boston-based clinical-stage oncology specialist Nuvalent for an equity value of approximately $10.6bn. This marks the British pharmaceutical giant’s largest transaction in over a decade. GSK will pay 124 dollars per share in cash for all outstanding Nuvalent common stock – a 40 per cent premium to Nuvalent’s previous closing stock price. The tender offer is scheduled…
GSK buying biopharmaceutical group 35Pharma for $950m
British multinational biopharmaceutical company GSK has reached a definitive agreement to acquire 35Pharma, a Canada-based clinical-stage biopharmaceutical company, for a total cash consideration of $950 million. The deal centres on 35Pharma’s lead asset, HS235, which is a potential best-in-class protein-based therapeutic designed to treat cardiopulmonary diseases. This investigational medicine has successfully completed phase I trials in healthy volunteers and is prepared…